Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.880
-0.010 (-0.53%)
At close: Mar 6, 2026, 4:00 PM EST
1.900
+0.020 (1.06%)
After-hours: Mar 6, 2026, 6:42 PM EST
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $257.15 million as of March 6, 2026. Its market cap has decreased by -8.60% in one year.
Market Cap
257.15M
Enterprise Value
179.83M
1-Year Change
-8.60%
Ranking
Category
Stock Price
$1.88
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $257.15M, an increase of 155.98%. That is a compound annual growth rate of 19.81%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 5, 2026 | 258.52M | -7.80% |
| Dec 31, 2025 | 280.40M | -3.25% |
| Dec 31, 2024 | 289.83M | 3,596.14% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 23, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Fennec Pharmaceuticals | 273.23M |
| Sol-Gel Technologies | 272.92M |
| ALX Oncology Holdings | 271.58M |
| Cellectis | 269.21M |
| Enlivex | 268.24M |
| Abeona Therapeutics | 267.71M |
| Shattuck Labs | 267.67M |
| Silence Therapeutics | 267.58M |